Synaptica B.V., founded by Dr. Marijn Martens, is at the forefront of revolutionizing epilepsy care. In collaboration with Artinis Medical Systems, they secured a 2-year MIT AI research grant to pioneer a novel approach using biologically realistic spiking neural networks. Together, they are developing an epilepsy headset for real-time seizure detection. Dr. Martens, a cognitive neuroscience expert, is leading the charge, aiming to enhance the precision of epilepsy diagnosis and treatment through innovative digital biomarkers. Synaptica’s mission is clear: to reshape the future of personalized neurocare by combining cutting-edge technology with neuroscience expertise.
Marijn Martens (PhD)
Complies with the following Sustainable Development Goals:
SDG 3: Good Health and Well-being